PDCD1 and neoplasm: This carries important clinical implications, because it highlights the importance of quantifying whole-tumor PD-L1 in a biopsy instead of focusing solely on tumor epithelial cells; current FDA guidelines for the administration of PD-1 blockade in HNSCC reflect this, using a PD-L1 scoring system that includes stromal PD-L1 expression47, although no similar guidelines exist for other SCCs.